Mark Breidenbach
Stock Analyst at Oppenheimer
(1.30)
# 3,595
Out of 5,058 analysts
52
Total ratings
30.91%
Success rate
-0.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.24 | +464.52% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $15.33 | +95.69% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $11.02 | +762.07% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $6.99 | +257.65% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.54 | +1,749.11% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $21.70 | +1,005.99% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.38 | +4,633.73% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.52 | +360.53% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.75 | +1,728.57% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $2.18 | +588.07% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.60 | +7,400.00% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.15 | +847,726.09% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.24
Upside: +464.52%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $15.33
Upside: +95.69%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $11.02
Upside: +762.07%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $6.99
Upside: +257.65%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.54
Upside: +1,749.11%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $21.70
Upside: +1,005.99%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.38
Upside: +4,633.73%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.52
Upside: +360.53%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.75
Upside: +1,728.57%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.18
Upside: +588.07%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.60
Upside: +7,400.00%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.15
Upside: +847,726.09%